⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AVXL News
Anavex Life Sciences
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
globenewswire.com
AVXL
Anavex Life Sciences to Present at the Citizens Life Sciences Conference
globenewswire.com
AVXL
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
globenewswire.com
AVXL
Form 8-K
sec.gov
AVXL
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
globenewswire.com
AVXL
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
globenewswire.com
AVXL
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
globenewswire.com
AVXL
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
globenewswire.com
AVXL
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm
prnewswire.com
AVXL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
prnewswire.com
AVXL